Article 1421

Title of the article

Studying the interaction of pentraxin-3 with parameters for assessing the course of chronic heart failure in patients with rheumatoid arthritis 

Authors

Andrey S. Ankudinov, Candidate of medical sciences, associate professor of the sub-department of simulation technologies and emergency medical care, Irkutsk State Medical University (1 Krasnogo Vosstaniya street, Irkutsk, Russia), E-mail: andruhin.box@ya.ru
Aleksey N. Kalyagin, Doctor of medical sciences, professor, head of the sub-department of propaedeutics of internal diseases, Irkutsk State Medical University (1 Krasnogo Vosstaniya street, Irkutsk, Russia), E-mail: akalagin@yandex.ru 

Index UDK

616.12-008.46-06.616 348-008.8-07 

DOI

10.21685/2072-3032-2021-4-1 

Abstract

Background. Immunomodulatory cytokines are currently actively used to assess the severity and predict the course of cardiovascular diseases, including heart failure. The purpose of the study was to compare laboratory-instrumental parameters and serum levels of pentraxin-3 in patients with chronic heart failure (CHF) with preserved and intermediate left ventricular ejection fraction against the background of rheumatoid arthritis (RA) and without RA, as well as to study possible associations of pentraxin-3 with laboratoryinstrumental indicators reflecting the severity of CHF. Materials and methods. The main group consisted of 134 patients with CHF with RA, and the comparison group consisted of 122 patients without RA. Functional class of CHF that participated in the study of patients according to NYHAI-II. The diagnosis of RA was made on the basis of X-ray and serological studies, which included the determination of the concentration of rheumatoid factor, antibodies to cyclic citrullinated peptide. The activity of the inflammatory process was assessed using the DAS28 index and the visual analog pain scale. X-ray stage of RA included in the study of patients I–III according to Steinbroker. The compared groups of patients had no differences in the nature and volume of therapy taken for heart failure. The basic anti - inflammatory drug for the treatment of RA is methotrexate. A biochemical and instrumental study was conducted. The processing was carried out using the program STATISTICA 10.0. The critical level of significance when testing statistical hypotheses is p < 0.05. Results. The concentration of atrial natriuretic peptide (NT-proBNP) was significantly lower in the group with RA compared to the group without RA: the level was 306.7 (225; 391) pg/ml; in the group without RA – 488.7 (355; 638) (p = 0.02). Comparative analysis of pentraxin-3 levels: 4.5 ± 0.9 and 1.5 ± 0.4, respectively (p = 0.001). An inverse association of pentraxin-3 and NT-proBNP was found in the group of CHF and RA (r = –0.1; p = 0.04). Conclusions. In the group of patients with CHF and RA, significantly increased levels of pentraxin-3 were observed against the background of an inverse association with NT-proBNP. 

Key words

pentraxin-3, chronic heart failure, rheumatoid arthritis 

Download PDF
References

1. Oganov R.G., Denisov I.N., Simanenkov V.I. Comorbid pathology in clinical practice. Clinical guidelines. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular therapy and prevention. 2017;16(6):5‒56. (In Russ.). doi:10.15829/1728-8800-2017-6-5-56
2. Nurmohamed M.T., Heslinga M., Kitas G.D. Cardiovascular comorbidity in rheumatic diseases. Nature Reviews Rheumatology. 2015;11(12):693‒704. doi:10.1038/ nrrheum.2015.112
3. Matsubara J., Sugiyama S., Nozaki T. Incremental prognostic significance of the elevated levelsof pentraxin 3 in patients with heart failure with normal left ventricular ejection fraction. Journal of the American Heart Association. 2014;3(3):e000928. Available at: https://www.ahajournals.org/doi/10.1161/JAHA.114.000928 (accessed 27.06.2021).
4. Mareev V.Yu., Fomin I.V., Ageev F.T. Clinical guidelines OSSN - RKO - RNMOT. Heart failure: chronic and acute decompensated. Diagnostika, profilaktika i lechenie. Kardiologiya = Diagnosis, prevention and treatment. Cardiology. 2018;58(6s):8‒158. (In Russ.). doi:10.18087/cardio.2475
5. Nasonov E.L. Revmatologiya. Klinicheskie rekomendatsii = Rheumatology. Clinical guidelines. Moscow: GEOTAR-Media, 2017:464. (In Russ.)
6. Aletaha D. Rheumatoid arthritis classification criteria: an American College of Rheumatology. European League Against Rheumatism collaborative initiative. Annals of the Rheumatic Diseases. 2010;69:1580‒1588. doi:10.1136/ard.2010.138461
7. Rebrova O.Yu. Statisticheskiy analiz meditsinskikh dannykh. Primenenie paketa prikladnykh programm STATISTICA = Statistical analysis of medical data. Application of the STATISTICA programmes. Moscow: MediaSfera, 2002:312. (In Russ.)
8. Filhol E., Gaujoux-Viala C., Combe B. Decrease in cardiovascular event excess risk in rheumatoid arthritis since 2000': a meta-analysis of controlled studies. Annals of the Rheumatic Diseases. 2017;76:1‒113. doi:10.1136/annrheumdis-2017-eular.4415
9. Logstrup B.B., Masic D., Laurbjerg T.B. Left ventricular function at two-year follow-up in treatment-naive rheumatoid arthritis patients is associated with anti-cyclic citrullinated peptide antibody status: a cohort study. Scandinavian journal of rheumatology. 2017;46(6):432‒440. doi:10.1080/03009742.2016.1249941

 

Дата создания: 22.02.2022 13:46
Дата обновления: 24.02.2022 13:11